HCPLive Network

NCPA: Access to Controlled Substances Often Delayed

THURSDAY, Jan. 16, 2014 (HealthDay News) -- Most pharmacists report experiencing multiple delays or issues with their controlled substance orders, according to the results of the National Community Pharmacists Association (NCPA) Controlled Substances Access Survey.

Members of the NCPA were surveyed in December 2013 regarding pharmacy access to controlled substances. More than 1,000 community pharmacists responded to the survey, which included an open-ended section to share observations.

According to the report, in the past 18 months, about 75 percent of respondents experienced three or more delays or issues with their controlled substance orders, which were caused by stopped shipments. On average, these delays affected 55 patients per pharmacy. Most pharmacies (89 percent) received no advanced notice of the delay, and only discovered the delay when their order arrived and included only non-controlled substances. The delays in receiving these medications lasted at least a week for 60 percent of the respondents. The majority of pharmacists (67.9 percent) reported being unable to obtain these substances from an alternate source. As a result, most pharmacies had to turn patients away and refer them to a competitor.

"Vulnerable patients are increasingly and tragically becoming collateral damage in the country's battle against the abuse of prescription drugs, particularly narcotic painkillers," Douglas Hoey, R.Ph., M.B.A., chief executive officer of the NCPA, said in a statement.

More Information


Copyright © 2014 HealthDay. All rights reserved.



Further Reading
A reliable set of emotion words have been identified that can serve as a tool for experience-based design questionnaires in health care, according to a study published in the December issue of Healthcare.
The rationale behind the decision making processes of the U.S. Food and Drug Administration is discussed in three articles published in the Jan. 22/29 issue of the Journal of the American Medical Association.
The question of whether to stop publishing research funded by the drug industry is addressed in a head-to-head piece published online Jan. 15 in BMJ.
Blogs can be a valuable tool to promote physician practices, according to an article published Dec. 17 in Medical Economics.
Human subjects protections policies do not provide regulatory coverage for all clinical trials, while up to about a quarter of trials are considered overlap trials, according to a research letter published in the March 5 issue of the Journal of the American Medical Association.
Keeping salaries secret hurts worker performance and increases turnover of top talent, according to a study published online Jan. 13 in the Academy of Management Journal.
Inconsistencies between ClinicalTrials.gov and medical journals’ reporting are raising questions about the editing and disseminating process.
More Reading